Sign In

Santaris Pharma A/S (acquired by Roche)

Santaris Pharma A/S is a clinical-stage biopharmaceutical company focussed on developing next generation RNA-silencing drugs based on its proprietary LNA® (Locked Nucleic Acid) technology for the treatment of cancer, metabolic disorders and other serious diseases. Created in May 2003 through a merger of Pantheco A/S and Cureon A/S, Santaris Pharma is backed by a broad group of leading international life-science venture capital investors.

• Show past press releases
• Edit this company

Elevator Pitch
Santaris Pharma’s drug pipeline is comprised of novel RNA Antagonist drugs based on its unique LNA® chemistry. Santaris Pharma holds the world wide patent rights to the exploitation of LNA in pharmaceuticals and presently has three drugs in preclinical or clinical development. The lead drug candidate, SPC2996, is currently undergoing an international, multicentre, phase I/II clinical study in Chronic Lymphocytic Leukemia (CLL).

Contact Information

Danish Science Park
Bøge Alle 3
Hørsholm DK 2970
+45 4517 9800
+45 4517 9898
Keith McCullagh
+45 4517 9800

Company Facts
Founded:May 2003
CEO:Keith McCullagh
CTO or technical lead:Henrik Ørum
CFO or finance director:Henrik Stage
Head of Sales:
Head of Marketing:

Category:Biotechnology & Healthcare
Funding raised:Yes
Funding sought:
Seeking Partnerships:No

Non-executive Board Members

  • Flemming Ørnskov, President and CEO, LifeCycle Pharma A/S
  • Claus Braestrup, CEO, Lundbeck A/S
  • Søren Carlsen, Managing Partner, Novo Ventures
  • Holger Reithinger, Principal, Global Life Science Ventures GmbH (GLSV)
  • Linda Sjøstrøm, Partner, BankInvest
  • Martien van Osch, Partner, Forbion Capital Partners
  • Walter Wenninger

    Key Customers

    Key Business Partners

    Key Competitors

    Capital Raised
    To view this information you must be signed in and subscribed to the online dataservice, sign in here.

    To read more about the Online data service click here

    Public Offerings
    No public offerings

  • Data

    Tech investments
    From our Online Data Service
    VC-backed companies
    From our Radar

    Recent Deals

    Nov 25€24.0MInternet commerce
    Jan 24€11.0MBiopharmaceuticals
    Jan 24N/ABiotechnology
    Jan 24€104.0MBusiness applications
    Jan 24€15.0MBiopharmaceuticals
    Jan 24€1.5MInternet services
    Jan 23€3.2MBusiness applications

    For information on Europe's most extensive database on technology funding click here!


    Press Releases

    May 28
    identiq raises $5m seed, launches privacy-first identity validation...

    Apr 29
    nethone raised over $1 million from innovation nest

    Oct 1
    The Link App
    the link app launches version 2.0

    Mar 29
    Addex Therapeutics
    addex sucessfully raises chf40 million in capital increase

    Jan 2
    Urban Jungle
    urban jungle raises £1m in seed funding to build tech-enabled home ...

    About usContact usLegal Information
    Copyright © 1999-2019
    Emerging Technology Research Europe Inc. All rights reserved.